<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01541397</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-MS-11-0119</org_study_id>
    <nct_id>NCT01541397</nct_id>
  </id_info>
  <brief_title>Bone Mineral Density in Adults With Hyperphenylalaninemia on Kuvan Therapy</brief_title>
  <official_title>Bone Mineral Density in Adults With Hyperphenylalaninemia on Kuvan Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BioMarin Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective study to compare the bone mineral density in adults with HPA on KUVAN™ therapy to&#xD;
      those not on therapy. The investigators hypothesize that after one year of KUVAN™ therapy,&#xD;
      there will be an improvement in their bone mineral density.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hyperphenylalaninemia (HPA) is a rare metabolic disorder caused by a deficiency of the enzyme&#xD;
      phenylalanine hydroxylase (PAH) (NIH, October 16-18, 2000). Elevated plasma levels of&#xD;
      phenylalanine (phe) cause mental retardation, microcephaly, delayed speech, seizures, eczema,&#xD;
      and behavior abnormalities. Adequate control of the plasma levels of phe by a phe-restricted&#xD;
      diet can prevent the developmental and behavioral problems.&#xD;
&#xD;
      The foundation of this diet is a phe-free metabolic medical product/formula made from free&#xD;
      amino acids. Based on longitudinal studies, it has been reported that the most benefit is&#xD;
      attained by individuals who maintain a phe-restricted diet throughout life. On December 13,&#xD;
      2007, KUVAN™ (sapropterin dihydrochloride) was approved by the FDA for the indication of&#xD;
      reducing blood phe levels in patients with HPA due to BH4 responsive PKU, in conjunction with&#xD;
      a phe restricted diet (BioMarin Pharmaceutical Inc., Investigator's Brochure March 25, 2008).&#xD;
      Studies were performed to determine a definition of response to KUVAN™. In a phase 2 clinical&#xD;
      trial in 2007, Burton, et. al. defined a Kuvan™ responder as having a 30% or greater&#xD;
      improvement in blood phenylalanine levels compared to baseline after 8 days of drug therapy.&#xD;
&#xD;
      Kuvan™ has been shown to improve phenylalanine tolerance in some individuals with HPA. This&#xD;
      drug enables these individuals to consume more protein from natural sources. However, there&#xD;
      have been no research studies assessing the effects of KUVAN™ along with liberalization of&#xD;
      the diet on bone mineral density.&#xD;
&#xD;
      The investigators propose a prospective study to compare the bone mineral density in adults&#xD;
      with HPA on KUVAN™ therapy to those not on therapy. The investigators hypothesize that after&#xD;
      one year of KUVAN™ therapy, there will be an improvement in their bone mineral density.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bone Mineral Density</measure>
    <time_frame>1 year after initiation of Kuvan therapy</time_frame>
    <description>A DXA scan will be conducted one year after Kuvan therapy is initiated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Amino Acid Profile</measure>
    <time_frame>every three months up to 1 year</time_frame>
    <description>Evaluation of levels of plasma amino acids.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diet Analysis</measure>
    <time_frame>every 3 months up to 1 year</time_frame>
    <description>Subjects will provide a 3 day diet record for every plasma amino acid evaluation. Diets will be analyzed to determine phenylalanine, protein, calories, fat, vitamins and minerals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Phenylalanine Levels</measure>
    <time_frame>weekly for 6 weeks, then at least every three months up to 1 year</time_frame>
    <description>Plasma phenylalanine levels will be monitored to determine effectiveness of Kuvan therapy.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Hyperphenylalaninemia</condition>
  <condition>Phenylketonuria</condition>
  <arm_group>
    <arm_group_label>Non-Kuvan treated</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Adults with hyperphenylalaninemia who have are not receiving Kuvan therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Kuvan treated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adults with hyperphenylalaninemia who are treated with Kuvan (sapropterin).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sapropterin</intervention_name>
    <description>20 mg/kg, orally, daily, 1 year or patient chooses to discontinue therapy</description>
    <arm_group_label>Kuvan treated</arm_group_label>
    <other_name>Kuvan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of hyperphenylalaninemia at birth&#xD;
&#xD;
          -  Age between 18 and 50 years&#xD;
&#xD;
          -  Participated in study HSC-MS-110-0262&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Peri-menopausal and menopausal women will be excluded because this is a time of&#xD;
             increased bone loss related to hormonal mediated factors.&#xD;
&#xD;
          -  Patients taking bisphosphonates because it alters bone density. Therefore, bone&#xD;
             mineral density would reflect the biphosphonate intervention rather than their true&#xD;
             status.&#xD;
&#xD;
          -  Pregnant women due to the hazard of radiation exposure during a DXA scan. In addition&#xD;
             women who have been pregnant or who have breastfed within one year of study enrollment&#xD;
             will be excluded because these are periods of rapid bone loss which would not reflect&#xD;
             the entity under study but would serve to confound the data.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heather W Saavedra, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center, Houston</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <study_first_submitted>July 11, 2011</study_first_submitted>
  <study_first_submitted_qc>February 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 1, 2012</study_first_posted>
  <results_first_submitted>June 11, 2015</results_first_submitted>
  <results_first_submitted_qc>June 11, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 7, 2015</results_first_posted>
  <last_update_submitted>June 11, 2015</last_update_submitted>
  <last_update_submitted_qc>June 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Heather Saavedra</investigator_full_name>
    <investigator_title>Nutritionist; Department of Pediatrics Division of Genetics</investigator_title>
  </responsible_party>
  <keyword>Hyperphenylalaninemia</keyword>
  <keyword>Phenylketonuria</keyword>
  <keyword>Adults</keyword>
  <keyword>Bone Mineral Density</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenylketonurias</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Non-Kuvan Treated</title>
          <description>Adults with hyperphenylalaninemia who have are not receiving Kuvan therapy.</description>
        </group>
        <group group_id="P2">
          <title>Kuvan Treated</title>
          <description>Adults with hyperphenylalaninemia who are treated with Kuvan (sapropterin).&#xD;
Sapropterin: 20 mg/kg, orally, daily, 1 year or patient chooses to discontinue therapy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Study ended prior to data collection</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Non-Kuvan Treated</title>
          <description>Adults with hyperphenylalaninemia who have are not receiving Kuvan therapy.</description>
        </group>
        <group group_id="B2">
          <title>Kuvan Treated</title>
          <description>Adults with hyperphenylalaninemia who are treated with Kuvan (sapropterin).&#xD;
Sapropterin: 20 mg/kg, orally, daily, 1 year or patient chooses to discontinue therapy</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Bone Mineral Density</title>
        <description>A DXA scan will be conducted one year after Kuvan therapy is initiated.</description>
        <time_frame>1 year after initiation of Kuvan therapy</time_frame>
        <population>Zero participants were analyzed because the study was ended early (due to an insufficient number of enrolled participants).</population>
        <group_list>
          <group group_id="O1">
            <title>Non-Kuvan Treated</title>
            <description>Adults with hyperphenylalaninemia who have are not receiving Kuvan therapy.</description>
          </group>
          <group group_id="O2">
            <title>Kuvan Treated</title>
            <description>Adults with hyperphenylalaninemia who are treated with Kuvan (sapropterin).&#xD;
Sapropterin: 20 mg/kg, orally, daily, 1 year or patient chooses to discontinue therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Mineral Density</title>
          <description>A DXA scan will be conducted one year after Kuvan therapy is initiated.</description>
          <population>Zero participants were analyzed because the study was ended early (due to an insufficient number of enrolled participants).</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Amino Acid Profile</title>
        <description>Evaluation of levels of plasma amino acids.</description>
        <time_frame>every three months up to 1 year</time_frame>
        <population>Zero participants were analyzed because the study was ended early (due to an insufficient number of enrolled participants).</population>
        <group_list>
          <group group_id="O1">
            <title>Non-Kuvan Treated</title>
            <description>Adults with hyperphenylalaninemia who have are not receiving Kuvan therapy.</description>
          </group>
          <group group_id="O2">
            <title>Kuvan Treated</title>
            <description>Adults with hyperphenylalaninemia who are treated with Kuvan (sapropterin).&#xD;
Sapropterin: 20 mg/kg, orally, daily, 1 year or patient chooses to discontinue therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Amino Acid Profile</title>
          <description>Evaluation of levels of plasma amino acids.</description>
          <population>Zero participants were analyzed because the study was ended early (due to an insufficient number of enrolled participants).</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Diet Analysis</title>
        <description>Subjects will provide a 3 day diet record for every plasma amino acid evaluation. Diets will be analyzed to determine phenylalanine, protein, calories, fat, vitamins and minerals.</description>
        <time_frame>every 3 months up to 1 year</time_frame>
        <population>Zero participants were analyzed because the study was ended early (due to an insufficient number of enrolled participants).</population>
        <group_list>
          <group group_id="O1">
            <title>Non-Kuvan Treated</title>
            <description>Adults with hyperphenylalaninemia who have are not receiving Kuvan therapy.</description>
          </group>
          <group group_id="O2">
            <title>Kuvan Treated</title>
            <description>Adults with hyperphenylalaninemia who are treated with Kuvan (sapropterin).&#xD;
Sapropterin: 20 mg/kg, orally, daily, 1 year or patient chooses to discontinue therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Diet Analysis</title>
          <description>Subjects will provide a 3 day diet record for every plasma amino acid evaluation. Diets will be analyzed to determine phenylalanine, protein, calories, fat, vitamins and minerals.</description>
          <population>Zero participants were analyzed because the study was ended early (due to an insufficient number of enrolled participants).</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Phenylalanine Levels</title>
        <description>Plasma phenylalanine levels will be monitored to determine effectiveness of Kuvan therapy.</description>
        <time_frame>weekly for 6 weeks, then at least every three months up to 1 year</time_frame>
        <population>Zero participants were analyzed because the study was ended early (due to an insufficient number of enrolled participants).</population>
        <group_list>
          <group group_id="O1">
            <title>Non-Kuvan Treated</title>
            <description>Adults with hyperphenylalaninemia who have are not receiving Kuvan therapy.</description>
          </group>
          <group group_id="O2">
            <title>Kuvan Treated</title>
            <description>Adults with hyperphenylalaninemia who are treated with Kuvan (sapropterin).&#xD;
Sapropterin: 20 mg/kg, orally, daily, 1 year or patient chooses to discontinue therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Phenylalanine Levels</title>
          <description>Plasma phenylalanine levels will be monitored to determine effectiveness of Kuvan therapy.</description>
          <population>Zero participants were analyzed because the study was ended early (due to an insufficient number of enrolled participants).</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Non-Kuvan Treated</title>
          <description>Adults with hyperphenylalaninemia who have are not receiving Kuvan therapy.</description>
        </group>
        <group group_id="E2">
          <title>Kuvan Treated</title>
          <description>Adults with hyperphenylalaninemia who are treated with Kuvan (sapropterin).&#xD;
Sapropterin: 20 mg/kg, orally, daily, 1 year or patient chooses to discontinue therapy</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Heather Saavedra</name_or_title>
      <organization>The University of Texas Health Science Center at Houston</organization>
      <phone>713-500-7098</phone>
      <email>Heather.Saavedra@uth.tmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

